Trial intelligence / Profile preview

CAPTIVATE phase 3 trial of DNTH103 in adults with chronic inflammatory demyelinating polyneuropathy

MOH_2025-11-04_015428Phase 3Not yet recruiting

Sponsor: Dianthus Therapeutics, Inc
Start: Aug 2025
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 3, randomised, double-blind trial of claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) (5 arms), sponsored by Dianthus Therapeutics, Inc. Planned start Aug 2025; status: not yet recruiting.

Drugs

claseprubart

Conditions

chronic inflammatory demyelinating polyneuropathy (CIDP)

Beyond the preview

Go deeper on MOH_2025-11-04_015428.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on MOH_2025-11-04_015428.